Proactive Investors - Run By Investors For Investors

Imugene Ltd appoints Leslie Chong to chief executive officer

Imugene Ltd (ASX:IMU) has promoted Leslie Chong to the position of chief executive officer, as the company prepares for the critical milestone of dosing the patients in the gastric cancer Phase 1b/2 clinical trial in Asia.
Imugene Ltd appoints Leslie Chong to chief executive officer
Imugene Ltd appoints Leslie Chong to chief executive officer

Chong joined IMU in September 2015 from the pharmaceutical giant, Genentech, in San Francisco where she had a distinguished career across many aspects of drug development.

Imugene is a clinical stage immuno-oncology company, with its lead product being HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.

The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

View full IMU profile View Profile

Imugene Ltd Timeline

October 19 2016

Related Articles

November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use